Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market ...
Medscape1mon
Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q.
The role of the classical and lectin complement pathways in GI/R injury was evaluated using C1q-deficient (C1q KO), MBL-A/C-deficient (MBL-null), complement factor 2- and factor B-deficient (C2/fB ...
News Medical on MSN3d
CD2AP and Alzheimer’s disease: A key regulator of neurodegeneration and potential therapeutic target
A comprehensive Thought Leaders Invited Review in Brain Medicine highlights the crucial role of CD2-associated protein (CD2AP ...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
(Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of ...
Renal & Urology News10d
Anti-C1q Antibodies in IgG4-Related Disease Associated With Renal and Skin Manifestations
Anti-C1q antibodies were present among 74.3% of patients with immunoglobulin G4-related disease. Anti-C1q antibodies are highly prevalent among patients with immunoglobulin G4-related disease ...
Yahoo Finance1mon
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting ...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
(Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of ...